Contractor Notice: Class 4 Drug Alert For Information / Action Rifadin (Rifampicin) 150mg Capsules

Contractor Notice: Class 4 Drug Alert For Information / Action Rifadin (Rifampicin) 150mg Capsules

October 16, 2019

Class 4 MHRA drug alert – Rifadin (rifampicin) 150mg Capsules (Aventis Pharma Limited t/a Sanofi)

Drug alert number: EL (19)A/25

Date issued: 16 October 2019

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for:

Rifadin (rifampicin) 150mg Capsules – PL 04425/5915R

Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet (PIL) for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required timeline. The affected batch details are:

Batch Number Expiry Date Pack Size First Distributed
9G020A 12/2021 1 x 100 16 October 2019

Advice for contractors 

When dispensing Rifadin (rifampicin) 150mg Capsules, please check the Marketing Authorisation Holder and the batch number. If dispensing the affected batch (9G020A) remove the PIL in the pack and provide a copy of the correct version, which can be downloaded from the link below:

https://www.medicines.org.uk/emc/product/6382/pil

Full details of the drug alert can be viewed here.

For medical information enquiries, please contact Sanofi Medical Information: Tel +44 (0) 845 372 7101; email uk-medicalinformation@sanofi.com.



Posted in: , ,


More Latest News >

CPCS Frequently Asked Questions

With the Community Pharmacist Consultation Service (CPCS) now bedding in, below you will find a selection of questions about the...

CPCS: CPD opportunities

As announced in the 5-year CPCF agreement, NHS England & NHS Improvement and Health Education England (HEE) will use funding...